Diabetic foot disease in a patient with multiple myeloma receiving thalidomide

Haematologica. 2002 Feb;87(2):ELT07.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Angiogenesis Inhibitors / therapeutic use
  • Collateral Circulation / drug effects
  • Combined Modality Therapy
  • Diabetes Mellitus, Type 1 / complications
  • Diabetic Foot / chemically induced
  • Diabetic Foot / etiology*
  • Diabetic Neuropathies / physiopathology
  • Endothelial Growth Factors / physiology
  • Female
  • Foot / blood supply
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Ischemia / chemically induced
  • Lymphokines / physiology
  • Male
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / therapy
  • Recurrence
  • Salvage Therapy
  • Thalidomide / adverse effects*
  • Thalidomide / therapeutic use
  • Thrombophilia / chemically induced
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Angiogenesis Inhibitors
  • Endothelial Growth Factors
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Thalidomide